Eczema Free Forever™

EU approves Sanofi and Regeneron’s dupilumab in eczema – Reuters


Reuters
EU approves Sanofi and Regeneron's dupilumab in eczema
Reuters
Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching. A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are …
Sanofi's Dupixent gets Europe eczema nodPharmaTimes
Sanofi, Regeneron claim EU approval for eczema drug DupixentPMLiVE
Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to …Markets Insider
pharmaphorum
all 7 news articles »

eczema – Google News

Eczema Free Forever™